ES2196632T3 - Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa. - Google Patents

Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa.

Info

Publication number
ES2196632T3
ES2196632T3 ES98961110T ES98961110T ES2196632T3 ES 2196632 T3 ES2196632 T3 ES 2196632T3 ES 98961110 T ES98961110 T ES 98961110T ES 98961110 T ES98961110 T ES 98961110T ES 2196632 T3 ES2196632 T3 ES 2196632T3
Authority
ES
Spain
Prior art keywords
complex
carragenine
pharmaceutical compositions
water soluble
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98961110T
Other languages
English (en)
Inventor
Carla Marcella Caramella
Maria Cristina Bonferoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Eurand International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand International SpA filed Critical Eurand International SpA
Application granted granted Critical
Publication of ES2196632T3 publication Critical patent/ES2196632T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un complejo de carragenina que tiene una viscosidad comprendida entre 500 y 2000 cPs medido a 37°C con una tasa de cizallamiento de 20 s exp(-1), con un medicamento en polvo soluble en agua con un tamaño de partículas medio que varía de 10 a 100 micrómetros y el medicamento básico soluble en agua está contenido en el complejo en cantidades que varían de 1, 5 a 5 mmol/g de carragenina.
ES98961110T 1997-10-29 1998-10-29 Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa. Expired - Lifetime ES2196632T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97PV000009A IT1297461B1 (it) 1997-10-29 1997-10-29 Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili

Publications (1)

Publication Number Publication Date
ES2196632T3 true ES2196632T3 (es) 2003-12-16

Family

ID=11397386

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98961110T Expired - Lifetime ES2196632T3 (es) 1997-10-29 1998-10-29 Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa.

Country Status (13)

Country Link
US (1) US6355272B1 (es)
EP (1) EP1030689B1 (es)
JP (1) JP2001521010A (es)
KR (1) KR20010031604A (es)
AT (1) ATE238070T1 (es)
AU (1) AU735337B2 (es)
BR (1) BR9813149A (es)
CA (1) CA2307863A1 (es)
DE (1) DE69813872T2 (es)
ES (1) ES2196632T3 (es)
IT (1) IT1297461B1 (es)
NZ (1) NZ504793A (es)
WO (1) WO1999021586A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
PL374280A1 (en) * 2001-11-13 2005-10-03 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
US8367098B2 (en) * 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US20040091528A1 (en) * 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
ES2336913T3 (es) * 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
CA2601716C (en) * 2004-06-25 2011-05-31 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
WO2006007354A2 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
JP2011068606A (ja) * 2009-09-25 2011-04-07 Kumamoto Univ 徐放性担体及び同徐放性担体を用いた薬剤並びに同薬剤を用いたドラッグデリバリーシステム
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US20130303632A1 (en) * 2012-05-10 2013-11-14 Fmc Corporation Controlled release solid dose form

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5227M (es) 1966-03-18 1967-08-14
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
DK171716B1 (da) 1982-03-12 1997-04-07 Pharmacia & Upjohn Ab Fremgangsmåde til fremstilling af et kompleks af carrageenan og emepronium, doxycyklin eller propranolol
JPS60174729A (ja) 1984-02-21 1985-09-09 Nippon Shinyaku Co Ltd 抗癌医薬組成物
US4613497A (en) * 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
JPS61130239A (ja) 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd 複合体
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
SE9103110D0 (sv) 1991-10-24 1991-10-24 Kabi Pharmacia Ab New drug formulation

Also Published As

Publication number Publication date
DE69813872D1 (de) 2003-05-28
KR20010031604A (ko) 2001-04-16
AU1665199A (en) 1999-05-17
EP1030689B1 (en) 2003-04-23
IT1297461B1 (it) 1999-12-17
WO1999021586A3 (en) 1999-07-08
EP1030689A1 (en) 2000-08-30
BR9813149A (pt) 2000-08-15
DE69813872T2 (de) 2004-02-26
ITPV970009A0 (it) 1997-10-29
CA2307863A1 (en) 1999-05-06
JP2001521010A (ja) 2001-11-06
ITPV970009A1 (it) 1999-04-29
AU735337B2 (en) 2001-07-05
NZ504793A (en) 2002-03-01
ATE238070T1 (de) 2003-05-15
WO1999021586A2 (en) 1999-05-06
US6355272B1 (en) 2002-03-12

Similar Documents

Publication Publication Date Title
ES2196632T3 (es) Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa.
SE9203594D0 (sv) Laekemedel i dispersa system
NO974404D0 (no) Insufflasjonsbærer for medikamenter med kontrollert frigivelse
BR0210425A (pt) Sistema de inalação com pó seco para administração transpulmonar
MY115688A (en) Pharmaceutical composition for administration by inhalation
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
CA2339992A1 (en) Orally disintegrable tablet forming a viscous slurry
ES2196382T3 (es) Administracion y envase de medicamentos.
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
BR0009604A (pt) Formulações de goma de mascar sobre-revestidas
ATE464885T1 (de) Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe
CY1107714T1 (el) Φαρμακευτικες συνθεσεις μοδαφινιλιου
NO20001042L (no) Oftalmiske preparater med forsinket frigivelse inneholdende vannoppløselige medikamenter
MX167175B (es) Sistema de entrega de drogas, con liberacion controlada, para la bolsa periodontal
HUP0101545A1 (hu) Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra
HUP9801414A2 (hu) Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
ATE239456T1 (de) Pharmazeutische formulierung in form eines trockenen pulvers
DE69925293D1 (de) Sprühbeschichtete mikropartikel für nadellose spritzen
WO2003053403A3 (en) Pharmaceutical suspension for oral administration
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso
ATE347886T1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
Pathak et al. Evaluation of compressibility of pentaestergum coated aspirin microcapsules
UA88256C2 (ru) Фармацевтические композиции модафинила, способ получения композиции модафинила и пероральная дозированная лекарственная форма